Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression

Development of bone marrow (BM) fibrosis and transformation to accelerated/blast phase are the main forms of disease progression in myeloproliferative neoplasms (MPN). Chronic myeloid leukemia, BCR-ABL1 -positive has several well-defined criteria that qualify for a diagnosis of accelerated phase (AP

[1]  U. Gianelli,et al.  Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.

[2]  A. Tefferi,et al.  Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model , 2019, Blood Cancer Journal.

[3]  A. Tefferi,et al.  Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis , 2018, British journal of haematology.

[4]  A. Tefferi,et al.  Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis , 2018, Blood Cancer Journal.

[5]  P. Guglielmelli,et al.  Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.

[6]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Tefferi,et al.  Monocytosis in polycythemia vera: Clinical and molecular correlates , 2016, American journal of hematology.

[8]  F. Fend,et al.  Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications , 2015, Modern Pathology.

[9]  M. Cazzola,et al.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.

[10]  F. Fend,et al.  Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease , 2013, Modern Pathology.

[11]  V. Jooste,et al.  Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients , 2013, British journal of haematology.

[12]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[14]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[15]  D. Dingli,et al.  Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. , 2007, Leukemia research.